Depemokimab: First Approval - PubMed
6 hours ago
- #asthma treatment
- #biologic approval
- #depemokimab
- Depemokimab (EXDENSUR) is an anti-IL-5 antibody developed by GSK for treating asthma and other eosinophilic conditions.
- It reduces asthma-related exacerbations in severe asthma with eosinophilic phenotype and decreases nasal polyps and obstruction in chronic rhinosinusitis with nasal polyps.
- First approved in the UK as an add-on maintenance treatment for asthma in patients aged ≥12 years with type 2 inflammation and inadequate control on inhaled corticosteroids.
- Also approved as add-on therapy with intranasal corticosteroids for severe chronic rhinosinusitis with nasal polyps inadequately controlled by systemic corticosteroids and/or surgery.